University of Jordan   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Amman Jordan (1962)

Organization Overview

First Clinical Trial
2007
NCT00825071
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Cell Therapy Center | Hanan Jafar | Jennifer Muhaidat | Saddam Al Demour | The university of Jordan | The University of Jordan | The University of Jordan School of Medicine | University of Jordan

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arrhythmias, Cardiac (Phase 4)

Bone Cysts (Phase 2)

Bone Cysts, Aneurysmal (Phase 2)

Cartilage Diseases (Phase 2)

Cysts (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 1)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Foot (Phase 2)

Diabetic Nephropathies (Phase 2)

Erectile Dysfunction (Phase 2)

Foot Ulcer (Phase 2)

Hypospadias (Phase 3)

Hypotension (Phase 3)

Inflammatory Bowel Diseases (Phase 2)

Intestinal Diseases (Phase 2)

Ischemia (Phase 2)

Kidney Diseases (Phase 2)

Multiple Sclerosis (Phase 2)

Nausea (Phase 4)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 2)

Pain, Postoperative (Phase 3)

Parkinson Disease (Phase 2)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 2)

Pharyngitis (Phase 4)

Postoperative Nausea and Vomiting (Phase 4)

Sclerosis (Phase 2)

Spinal Cord Injuries (Phase 2)

Ulcer (Phase 2)

Vitamin D Deficiency (Phase 2)

Vomiting (Phase 4)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial APIs: 39